Cargando…
Design and evaluation of oral formulation for apixaban
Non-valvular atrial fibrillation (NVAF) is a common form of cardiac arrhythmia that affects 1–1.5% of adults and roughly 10% of elderly adults with dysphagia. Apixaban is an anticoagulant referred to as a factor Xa inhibitor, which has been shown to reduce the risk of stroke and systemic embolism in...
Autores principales: | Wang, Chien-Chiao, Chen, Yu-Li, Lu, Ta-Chien, Lee, Catherine, Chang, Yu-Chia, Chan, Yen-Fan, Mathew, Philip, Lin, Xing-Rong, Hsieh, Wen-Rung, Huang, Ting-Yun, Huang, Hsin-Lan, Hwang, Tsong-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391955/ https://www.ncbi.nlm.nih.gov/pubmed/37534003 http://dx.doi.org/10.1016/j.heliyon.2023.e18422 |
Ejemplares similares
-
Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018) -
Apixaban and oral implications
por: Lopez-Galindo, Monica, et al.
Publicado: (2015) -
Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
por: Lee, Juseung, et al.
Publicado: (2023) -
Spatio-temporal analysis on enterovirus cases through integrated surveillance in Taiwan
por: Chan, Ta-Chien, et al.
Publicado: (2014) -
Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)